$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
二代白血病药物达沙替尼能完全控制白血病吗?
2025-10-19 11:44:20
Check Details
米哚妥林是获批用于治疗急性髓性白血病的药物
2025-10-19 11:44:20
Check Details
慢性髓细胞白血病吃达沙替尼要吃多长时间?
2025-10-19 11:44:20
Check Details
FDA批准的首个分子靶向药物-米哚妥林
2025-10-19 11:44:20
Check Details
米哚妥林适用于治疗哪种白血病的治疗?
2025-10-19 11:44:20
Check Details
伊马替尼耐药后可换成尼洛替尼继续治疗
2025-10-19 11:44:20
Check Details
米哚妥林联合化疗治疗急性髓性白血病的效果
2025-10-19 11:44:20
Check Details
达沙替尼治疗慢性髓细胞白血病的疗效和安全性
2025-10-19 11:44:20
Check Details
用达沙替尼治疗白血病能延长多久的生存期?
2025-10-19 11:44:20
Check Details
慢性髓细胞白血病患者服用达沙替尼需要了解的事项
2025-10-19 11:44:20
Check Details
美国FDA批准达沙替尼用于儿童白血病的治疗
2025-10-19 11:44:20
Check Details
米哚妥林用于急性骨髓性白血病(AML)的安全性及有效性
2025-10-19 11:44:20
Check Details
1
2
...
592
593
594
595
596
597
598
...
935
936
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olutasidenib: Mechanism of Action and Clinical Guide for IDH1-Mutated AML
2
Gilteritinib: Efficacy, Medication Guide and Latest Advances for FLT3-Mutated AML
3
Common Adverse Reactions and Clinical Safety Management of Gilteritinib (Xospata)
4
Adverse Reaction Profile and Clinical Safety Management of Idelalisib
5
Clinical Significance of Platelet Recovery During Revumenib (Menin Inhibitor) Therapy
6
A Key Therapeutic Breakthrough Against T315I-Mutant CML
7
Tafasitamab: An Fc-Enhanced CD19-Targeted Immunotherapy for B-Cell Malignancies
8
Tafasitamab and Lenalidomide Combination Therapy Guide
9
Pirtobrutinib (Jaypirca) Medication Guide: Overcoming BTK Resistance & Safety Management
10
Gilteritinib Professional Medication Guide & Dosage Management
11
Pirtobrutinib: A Novel Non-Covalent BTK Inhibitor for Relapsed Hematologic Malignancies
12
Clinical Application and Safety Monitoring of Revumenib (Menin Inhibitor) in Acute Leukemia